Literature DB >> 25522600

[Advance in studies on molecular mechanisms of cisplatin resistance and intervention with traditional Chinese medicines].

Lei Liu, Ka Bian.   

Abstract

Cisplatin is a first-line anticancer drug widely used in clinic. However, its resistance reduces its efficacy. With a non-specific cell cycle, cisplatin's main targets are nucleophilic protein, DNA and RNA in cells. Among cisplatin's multi-factorial resistance mechanisms, abnormal expression of transport protein, intracellular detoxification enhancement, DNA repair capacity increase and apoptosis blocking are the main mechanisms. Because traditional Chinese medicines (TCMs) have unique advantages in cancer treatment, their combination with cisplatin can improve the efficacy. In this paper, the authors summarized the advance in studies on cisplatin's resistance and the combination of TCMs and cisplatin in recent years.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25522600

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  3 in total

1.  Non-SMC condensin I complex subunit H promotes the malignant progression and cisplatin resistance of breast cancer MCF-7 cells.

Authors:  Linhong Liao; Hui Cheng; Shusong Liu
Journal:  Oncol Lett       Date:  2022-07-19       Impact factor: 3.111

2.  The synergistic antitumor effect of cinobufagin and cisplatin in human osteosarcoma cell line in vitro and in vivo.

Authors:  Guo Dai; Ling Yu; Jian Yang; Kezhou Xia; Zhengpei Zhang; Gaiwei Liu; Tian Gao; Weichun Guo
Journal:  Oncotarget       Date:  2017-07-25

3.  Whole genome gene expression changes and hematological effects of rikkunshito in patients with advanced non-small cell lung cancer receiving first line chemotherapy.

Authors:  Yung-Che Chen; An-Shen Lin; Yu-Chiang Hung; Kuang-Den Chen; Ching-Yuan Wu; Chien-Hao Lie; Chang-Chun Hsiao; Chung-Jen Chen; Shih-Feng Liu; Wen-Feng Fang; Jen-Chieh Chang; Ting-Ya Wang; Yi-Hsi Wang; Yu-Hsiu Chung; Tung-Ying Chao; Sum-Yee Leung; Mao-Chang Su; Meng-Chih Lin
Journal:  Exp Ther Med       Date:  2017-07-11       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.